McNeil implements corrective action plan
In the wake of a product recall that included more than 50 million units of Tylenol arthritis products, St. Joseph's Aspirin, Motrin and other products, the McNeil Consumer Healthcare unit of Johnson & Johnson reported that it has taken steps to ensure that similar situations do not happen in the future. In a letter to the U.S. Food and Drug Administration, Peter Luther, McNeil president, wrote, “McNeil and Johnson & Johnson management are taking this issue very seriously and are committed to ensuring that McNeil implements all necessary corrective and preventive actions to improve the McNeil quality systems.” The letter also outlined key elements of the corrective action plan that includes enhancements to the quality system, organizational changes, and senior management oversight. For more, go to Modern's Web site, mmh.com/recall.
